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To date, there are no studies of the TGF-b
superfamily of signaling pathways across
multiple cancers. This study represents a
key starting point for unraveling the role of
this complex superfamily in 33 divergent
cancer types from over 9,000 patients..
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Wepresent an integromic analysis of gene alterations
that modulate transforming growth factor b (TGF-b)-
Smad-mediated signaling in 9,125 tumor samples
across 33 cancer types in The Cancer Genome Atlas
(TCGA). Focusing on genes that encode mediators
and regulators of TGF-b signaling, we found at least
one genomic alteration (mutation, homozygous dele-
tion, or amplification) in 39%of samples, with highest
frequencies in gastrointestinal cancers.We identified
mutation hotspots in genes that encode TGF-b li-422 Cell Systems 7, 422–437, October 24, 2018 ª 2018 The Authors.
This is an open access article under the CC BY-NC-ND license (http://gands (BMP5), receptors (TGFBR2, AVCR2A, and
BMPR2), and Smads (SMAD2 and SMAD4). Alter-
ations in the TGF-b superfamily correlated positively
with expression of metastasis-associated genes
and with decreased survival. Correlation analyses
showed the contributions of mutation, amplification,
deletion, DNA methylation, and miRNA expression
to transcriptional activity of TGF-b signaling in each
cancer type. This study provides a broad molecular
perspective relevant for future functional and thera-
peutic studies of the diverse cancer pathways medi-
ated by the TGF-b superfamily.Published by Elsevier Inc.
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. TGF-b Pathway and Its Genomic Alterations in Cancer
(A) The canonical TGF-b pathway. TGF-b superfamily member ligands bind to type II receptors, leading to recruitment and activation of type I receptors through
phosphorylation.Subsequently, theactivatedreceptorsphosphorylate intracellularR-SMADs, suchasSMAD2andSMAD3,whichbind to the receptor throughadaptor
molecules.TheR-SMAD/co-SMAD(SMAD2/3-SMAD4)complex is transported into thenucleus to induce transcriptionalprograms regulatedby theTGF-bsuperfamily.
(B) Landscape of genomic aberrations in the TGF-b superfamily genes in cancer. The frequency of alterations in TGF-b superfamily ligands, receptors and re-
ceptor-associated proteins, intracellular SMADs, and adaptor molecules are presented. Only samples with genomic alterations in the indicated genes are shown
in each oncoprint. Alteration rates per gene and gene family are displayed in the left and top labels, respectively.
See also STAR Methods; Figure S1; Tables S1 and S2.INTRODUCTION
The transforming growth factor b (TGF-b) superfamily of ligands
activates Smad proteins to regulate transcription and control cell
proliferation and differentiation. The TGF-b pathways are
context-dependent signal transduction cascades that can
promote seemingly contradictory cell processes, including pro-
motion of differentiation and tumor growth, inhibition of cell pro-
liferation, suppression of immune response, and maintenance of
stem cell homeostasis (Akhurst, 2017; Colak and Ten Dijke,
2017; Seoane and Gomis, 2017; Christian and Heldin, 2017;
Moustakas and Heldin, 2016; Mishra et al., 2005; Wakefield
and Roberts, 2002). Animal models of mammary gland tumori-
genesis support a pro-tumorigenic role for signaling by the
TGF-b1-Smad2 pathway (Muraoka-Cook et al., 2004), whereas
mouse models of gastrointestinal (GI) cancers and hepatocellu-
lar cancers indicate a primarily tumor-suppressive role (Chen
et al., 2018; Chen et al., 2016b; David et al., 2016; Katz et al.,
2016). In pancreatic KRAS-mutant premalignant cells, TGF-b
signaling induces expression of metastasis-promoting genes
(David et al., 2016) and apoptosis-regulatory genes. Thus,
even within a single subfamily of ligands that act through the
same downstream Smad complexes, the net outcome can be
either tumor-suppressing or tumor-promoting depending on
the context. Hence, predicting appropriate TGF-b-based thera-
peutic interventions is challenging.
To dissect the context-specific roles of the TGF-b pathway
across multiple cancer types, we focused on 43 core genes that
regulate or mediate TGF-b signaling. We selected the core genes
through consensus of The Cancer Genome Atlas (TCGA) TGF-b
network members, although we acknowledge that the process of
identifying a core subset of genes is inherently subjective to some
degree. The ‘‘integromic’’ analysis (Weinstein, 2006) describedhere reveals potential nodesof crosstalkwith other cancer-relevant
pathways, and it enables prediction of the activity of TGF-b-Smad
pathways in various cancer contexts. The data and analyses pro-
vide a rich resource for understanding TGF-b biology, with the po-
tential to identify context-dependent therapeutic targets.
RESULTS
We focus here on the genomic, epigenomic, and transcriptomic
landscapeof 43genes that encodeproteins thatmediate or regu-
late signaling by the TGF-b superfamily and 50 downstream
target genes of Smad-dependent signaling in 9,125 patients
across 33 TCGA tumor types (https://tcga-data.nci.nih.gov/
docs/publications/tcga/) (Table S1), referred to as the ‘‘Pan-Can-
cer cohort.’’ The analysis is limited to this set of TGF-b pathway-
related genes and yet represents a valuable starting point to
examine TGF-b signaling across multiple cancers. We analyzed
multiple data types: somatic copy number variation (CNV), point
mutation,DNAmethylation,mRNAexpression (frommRNA-seq),
miRNA expression (from miRNA-seq), and, for correlative ana-
lyses, protein expression (from reverse-phase protein arrays
[RPPA]). The datawere corrected for batch effects and other sys-
tematic biases prior to analysis (see STAR Methods).
Selection of Genes Associated with the TGF-b
Superfamily
The list of 43 ‘‘core’’ TGF-b genes includes 2 genes encoding
adaptor proteins (SPTBN1 and ZFYVE9) that are important in
TGF-b signaling and play roles in other cellular processes. The
other 41 genes encode components of each level of the ‘‘canon-
ical’’ TGF-b signaling pathway that activates Smads to regulate
gene expression (Figure 1A): 3 TGF-b ligands, 8 bonemorphoge-




Figure 2. Pan-Cancer Genomic Analysis of the 43 TGF-b Superfamily Pathway Genes in 33 Cancer Types
(A–C) Distribution of genomic alterations over cancer types. (A) Non-silent somatic mutations, (B) copy number amplifications, and (C) homozygous deletion
frequencies. SKCM, UCEC, STAD, and COAD show high overall mutation rates.
(legend continued on next page)
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receptors and 1 interacting protein (TGFBRAP1), 3 BMP recep-
tors, and 6 ACV receptors; and 8 Smads (Figure 1B). The list of
43 genes is available at cBioPortal (http://www.cbioportal.org)
as ‘‘General: TGF-b superfamily.’’ Noncanonical signaling (Fig-
ure S1A) is excluded from this analysis. Figure S1B shows pair-
wise correlation coefficients of the 43 genes.
To explore the effect of TGF-b pathway genomic alterations on
transcriptional output and to validate pathway activity, we
selected a panel of 50 downstream target genes that are regu-
lated by TGF-b-Smad signaling and have important roles in
epithelial-to-mesenchymal transition (EMT), metastasis, or tu-
mor suppression (Table S1).
Genomic Alterations in TGF-b Superfamily Genes
We performed mutation and CNV analyses of the 43 genes to
identify genomic aberrations across the Pan-Cancer cohort (Fig-
ure 1B and Table S2). Using the cBioPortal definitions (Cerami
et al., 2012), genomic alterations were classified as gene ampli-
fications, gains (low-level amplifications), deep deletions (equiv-
alent to homozygous deletions for non-aneuploidy cases),
shallow deletions (heterozygous loss), truncating mutations, in-
framemutations, or missensemutations. We use the term ‘‘alter-
ation’’ henceforth for mutations (truncating or missense) and
CNVs (deep deletion or amplification). Oncoprint representation
from cBioPortal revealed the distribution of TGF-b genomic al-
terations in the Pan-Cancer cohort (Figure 1B). Although alter-
ation frequencies were low, 39% of the tumors contained an
alteration in at least one of the 43 genes. SMAD4 (4%) and
SPTBN1 (4%) were the most frequently altered. Collectively,
BMP ligands had an alteration frequency of 13%. Six genes
(GDF1, GDF11, SMAD6, SMAD7, INHBE, and NODAL) had mu-
tation frequencies <0.5% (Table S2). When excluding those six,
cumulative mutation frequency (23%) in the TGF-b core path-
ways was significantly higher than expected for a randomly
selected set of 37 genes (Figures S1C and S1D). A set of genes
in the TGF-b superfamily had recurrent chromosomal deletions
of at least one allele (Figure S1E). Heterozygous deletions gener-
ally occur with high frequency in tumor suppressor genes and
may be accompanied by additional mutations in the remaining
allele, leading to complete loss of tumor suppressor function
(Haverty et al., 2009). All SMAD-encoding genes had heterozy-
gous deletion frequencies greater than 20%, with several
exceeding 30%. Tumors rarely had more than one mutationally
altered gene within a category.
Distribution of Gene Alterations across Cancer Types
The frequency and type of genomic alteration varied widely
across tumor types (Figures 2A and S2A), from no alterations
in testicular germ cell tumors (TGCT) to all three types of alter-
ations (mutation, deletion, and amplification) in urothelial bladder
cancers (bladder urothelial carcinomas [BLCAs]). There were
genomic alterations of TGF-b pathway genes in more than
50% of samples in 12 tumor types (Figure 2A and Tables S2,(D–F) Statistical significance of alterations in the TGF-b superfamily pathway gen
based on MutSigCV results (D) and GISTIC2 (E and F) analyses. Only the genes
(G–I) Transcriptional output associated with alterations in the TGF-b superfamily p
TGF-b superfamily pathways, including mutations (G), amplifications (H), and de
See also Figure S2 and Tables S2, S3, and S4.S3, and S4). Skin cutaneous melanoma (SKCM), colon adeno-
carcinoma (COAD), esophageal carcinoma (ESCA), stomach
adenocarcinoma (STAD), and uterine corpus endometrial carci-
noma (UCEC) had high background alteration burdens, including
microsatellite instability (MSI) or chromosomal instability (CIN)
(Cancer Genome Atlas Network, 2012; Cancer Genome Atlas
Network, 2015; Cancer Genome Atlas Research Network et al.,
2013). Without adjusting for background alteration burden,
among the 39% of TCGA cases that carried TGF-b pathway
gene alterations, SKCM (70%), COAD (65%), and ESCA (65%)
had the highest percentages of alterations; thyroid carcinoma
(THCA) (4%), kidney chromophobe (KICH) (6%), and TGCT
(9%) had the lowest (Table S3).
We observed non-silent SMAD4 mutations in 24% and
SMAD4 deletions in 13% of pancreatic adenocarcinoma
(PAAD) samples (Figures 2A and 2C and Table S4). Because
SMAD4 is the Co-Smad required for transducing the Smad
signal to downstream effectors, loss of SMAD4 in PAAD by mu-
tation or deletion suggests a tumor-suppressive role for TGF-b
signaling in PAAD, which is consistent with other reports (David
et al., 2016).
Among all cancer types, high-grade ovarian cancers (OVs)
(Figure 2B) had high amplification frequency, which could be
due to genomic instability (Cancer Genome Atlas Research
Network, 2011). Prostate adenocarcinoma (PRAD) had the
highest deletion frequency, marked by losses in the SMAD9
(encoding a Receptor-Smad [R-Smad]) and ACVR2A (encoding
a receptor) (Figures 2B and 2C). Rectal adenocarcinoma
(READ) had the greatest frequency of BMP7 amplification.
Diffuse large B-cell lymphoma (DLBC) had a high frequency of
deletions spanning different levels of the pathway—ligands
(TGFB2, INHBB, and GDF1), receptors or receptor-associated
proteins (BMPR1A, ACVR1, ACVR1C, ACVR2A, ACVR2B, and
TGFBRAP1), and Smads (SMAD9)—indicative of a tumor-sup-
pressive role for TGF-b signaling in these early-stage DLBC
cases in the TCGA cohort.
After adjusting for background alteration burden, we analyzed
MutSigCV- and GISTIC-precomputed results across all individ-
ual cancer types and the Pan-Cancer cohort to identify signifi-
cantly mutated genes (SMGs) and genes targeted by somatic
CNVs (Figures 2D–2F). The analysis revealed SMAD4, ACVR2A,
and TGFBR2 as themost common SMGswithin specific disease
types and across the Pan-Cancer cohort. SMAD4 had a highly
overlapping profile with TGFBR2; both were SMGs in the GI can-
cers PAAD, ESCA, and STAD. Among individual disease types,
COAD had the highest number of SMGs (SMAD4, SMAD3,
SMAD2, and ACVR2A). The number of genes targeted by so-
matic CNVs, particularly deletions, was higher than the number
of SMGs (Figures S1C, S2B, and S2C). A common type of
CNV was recurrent heterozygous loss (Figure S1E). SMAD4
was the only statistically significant deletion target in the Pan-
Cancer cohort; it was most significantly deleted in GI cancers
(PAAD, COAD, READ, STAD, and ESCA). PAAD had deletionses. Genes that were significantly mutated or targets of copy-number alteration
altered significantly in at least one cancer type are included.
athway genes. Differential mRNA expression of key genes downstream of the
ep deletions (I).
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associated with 14 TGF-b core genes, suggesting synergistic ef-
fects from ligands (BMP family), receptors (BMPR, TGFBR), and
SMAD4. Colorectal cancers (COAD and READ) were marked by
SMAD4 and SMAD3 deletions. Deletions in genomic regions
covering all ACVR genes except ACVR2B were identified as sig-
nificant in DLBC.
Transcriptional Signatures of Genomic Alterations in
the TGF-b Pathways
To understand how gene alterations affect transcriptional output
of the pathways, we analyzed the mRNA expression of 50 down-
stream targets of Smad signaling with defined roles as tumor
promoters or tumor suppressors (Table S1). Unsupervised hier-
archical clustering analysis identified patterns of correlation
between target gene expression and each class of genomic
alteration (Figures 2G–2I). Point mutations were associated
with two predominant patterns of target gene signatures:
increased or decreased expression (Figure 2G). Surprisingly,
the directionality of target-gene change was consistent for all
mutations, even for mutations in the inhibitors SMAD6/7. An
explanation is that mutations in pathway activators, such as
TGFB1/2/3 and TGFBR1/2/3, may result in gain of function,
whereas mutations in the inhibitors SMAD6 and SMAD7 may
result in loss of inhibitory function.
Another explanation is thatSMAD2was generally co-amplified
with SMAD7 (Figure 1B); both genes are in the same cytogenetic
band (18q21.1). Similarly, SMAD3 was generally co-amplified
with SMAD6; both are in proximal cytogenetic bands,
15q22.33 and 15q22.31, respectively. Thus, the net effect of
those co-amplifications could be an overall increase in pathway
activity. In support of that hypothesis, both the amplification and
deletion profiles (rows in Figures 2H and 2I) of those gene pairs
were similar, and consequently, SMAD2 and SMAD7 are co-
clustered, whereas SMAD3 and SMAD6 are clustered close to
each other.
The effect of TGF-b pathway amplification events on target
gene mRNA expression was similar to that of mutations (Fig-
ure 2H), suggesting that most mutations in TGF-b pathway acti-
vators are gain-of-function. HMGA2 (encoding a chromatin
remodeling protein with oncogenic properties; Morishita et al.,
2013; Thuault et al., 2006) was overexpressed in samples with
either mutations or amplifications in the TGF-b pathway genes,
with the exception of tumors with amplifications in TGFB2,
TGFBR2, ACVR2B, SMAD4, SMAD5, or SMAD6. Those 6 genes
may deliver context-specific signals for regulating HMGA2
expression. Likewise, CDH2 clustered separately from other
genes, and its decreased expression was associated with
most point mutations and CNVs. CDH2 encodes a cadherin
important in cell adhesion and migration (Principe et al.,
2014; Xu et al., 2009). Another distinct cluster contained over-Figure 3. Mutational Hotspots in the TGF-b Superfamily Pathways
(A) Recurrent hotspot sites. Hotspot mutations with >9 incidents are labeled. Mut
separated by slashes. Del, deletions; fs, frameshifts; asterisks, stop codons.
(B) Transcriptional output of pathway hotspot mutations in GI and Pan-Cance
quantified in relation to 6 hotspot mutations in the Pan-Cancer cohort (left) and G
(C) SMAD4 R361C/H/P/S. R361 is located on the SMAD4 homotrimer interaction
(D) ACVR2A K437E. K437 is marked on the structure of the ACVR2A C-terminal
(E) SMAD2. Position and putative effect of the C-terminal truncation mutation S4
See also Figure S3.expressed metastasis-related genes, including collagens
(COL1A1/1A2/3A1), a metalloprotease (MMP9), and a transcrip-
tion factor (FOXP3).
SMAD5 amplification was associated with increased CDH2
expression; 36 other amplifications were associated with
decreased CDH2 expression. Similarly, HMGA2 expression
was increased with most amplification events but decreased
where SMAD5 was amplified (Figure 2H). Another exception
was reduced HMGA2 expression in samples with amplifications
of SMAD4 or TGFBR2, whereasHMGA2 expression increased in
samples with mutations in SMAD4 or TGFBR2 (Figure 2G).
Hotspot Mutations in Genes Associated with TGF-b
Superfamily Pathways
We focused on sites in the 43 genes that were mutated in at least
9 samples across the 33 tumor types (see Figure S3 for hotspot
mutations identified within at least 5 samples). The analysis iden-
tified 6 genes with hotspot mutations, representing all levels of
the TGF-b pathway (Figures 3A–3E). BMP5 and TGFBR2
included previously unreported hotspots.
Hotspot mutations of BMP5 occurred in 13 cases across 7
cancers. BMP5 is synthesized as a proprotein, and an R321
stop-codon mutation (4 cases) (Figure 3A) results in loss of the
functional secreted ligand. An R321 to Q (9 cases) mutation
may impact cleavage of the protein to the mature secreted
form. Frameshift mutations in ACVR2A at the K437 hotspot
generate the variants K437Efs*19 (7 cases in 2 cancers) and
K437Rfs*5 (69 cases in 5 cancers), resulting in premature stop
codons and deletion of 2 C-terminal helices of the 4-helix bundle
(Figures 3A and 3D), which likely disrupt ACV signaling (Rossi
et al., 2005). Type I receptors ACVR1B and ACVR1C have similar
C-terminal frameshift mutation hotspots at R485 (6 cases) and
R441 (5 cases), respectively (Figure S3). TGFBR2 R553 to C or
H mutations and BMPR2 N583 frameshift might disrupt interac-
tion with other receptor subunits or binding proteins (Chan et al.,
2007). Hotspots in SMAD4 at R361 and D537 (two conserved
sites in R-Smads) (Shi et al., 1997) normally stabilize homo- or
heterotrimer oligomerization (Figure 3C) (Fleming et al., 2013;
Shi et al., 1997). Those mutations could have widespread effects
because SMAD4 is a binding partner for all Smad-dependent
transcriptional regulation. Mutation at either R361 or D537 in
SMAD4 correlates with metastasis and decreased survival in
colon cancer (Mehrvarz Sarshekeh et al., 2017). SMAD2 ex-
hibited 13 truncating mutations at S464 (Figure 3A). S464 is
part of the essential phosphorylation motif SSXS (Ser464-
Ser465-X466-S467) of R-SMADs (Fleming et al., 2013) (Fig-
ure 3E). S464 is necessary for proper positioning of SMAD2 for
phosphorylation at S465 and S467, both of which mediate inter-
action of SMAD2 with SMAD4 (Macias et al., 2015) and dissoci-
ation of SMAD2 from TGFBR1 and the adaptor SARA (encodedations that result in substitutions are indicated by single-letter amino acid code
r cohorts. Differential mRNA expression of 50 TGF-b pathway target genes
I cancers (right).
interface, as shown on the SMAD4 structure (PDB ID: 1DD1).
kinase domain (PDB ID: 4ASX).
64* are shown.
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Figure 4. Comparison of TGF-b Superfamily Pathway Activity and Gene Aberrations
(A) The TGF-b superfamily pathway gene expression signature in GI cancers. Heatmap indicating the effects of non-silent somatic mutations in the 43 TGF-b
pathway genes on expression of downstream target genes for 1,511 samples of 5 GI cancer types. Color reflects the log ratio of median expression in samples
that carry the alteration versus samples that are wild-type (y axis).
(legend continued on next page)
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by ZFYVE9). Hence, S464mutations may prevent dissociation of
SMAD2 from the receptor-adaptor complex, blocking the down-
stream signal (Figure 3E).
GI Cancers Are Enriched with TGF-b Pathway Hotspot
Mutations
Of 176 mutations at hotspot sites across 6 genes, 115 (65%)
were in cancers of the GI system (Figure S3): 60 in ESCA, 51 in
COAD, 3 in PAAD, and 1 in liver hepatocellular carcinoma
(LIHC). The connection to GI cancers is also supported by other
studies (Park et al., 2010; Mehrvarz Sarshekeh et al., 2017). We
found the reported SMAD4 and BMPR2 hotspots (Park et al.,
2010; Mehrvarz Sarshekeh et al., 2017) and identified hotspots
in BMP5 and TGFBR2.
To determine if GI cancers possess a unique signature of
altered TGF-b pathway activity, we compared changes in the
expression of 50 downstream genes related to mutations at hot-
spot sites (Figure 3B). The expression signatures associatedwith
the BMP5 hotspot clustered separately from those associated
with other hotspots. Notably, CDH2 exhibited an overall reduc-
tion in expression, except in the context of the BMP5 hotspot
mutation. A cluster of genes (HMGA2, TERT, MMP9, COL1A1/
1A2/3A1,MYC, FOXP3, and IL6) exhibited increased expression
in the GI cancers containing at least one of the 6 hotspot muta-
tions. Unique to the GI tumors was a cluster of genes that
included strongly reduced expression of CDH2, ALDH1A1, and
IGF2 and a cluster with moderately reduced expression of
SERPINE1.
When compared with the Pan-Cancer cohort, the GI subset
showed an association of hotspot mutations with less expres-
sion of downstream genes (Figure 3B). That trend was generally
characterized by blunted upregulation of the upregulated genes
(HMGA2, collagen encoding genes, FOXP3, MMP9, and MYC)
and greater downregulation of the downregulated genes
(ALDH1A1 and CDH2).
Transcriptional Signatures of TGF-b Pathway
Alterations in GI Cancers
Guided by the enrichment of hotspotmutations inGI cancers, we
tested for enrichment of TGF-b pathway point mutations in GI
cancers. Non-silent mutations were significantly more common
in GI cancers (596 of 1,511) than in the non-GI cancers (1,606
of 7,614). Deep deletions and amplifications were also signifi-
cantly enriched in GI cancers. COAD, READ, and STAD had
recurrent aberrations in genes at each level of the pathway (li-
gands, receptors, and SMADs) and all axes (TGFBR, BMPR,
and ACVR), whereas PAAD had frequent mutations in only
SMAD4 and TGFBR2 (Figure S4A).(B) The TGF-b superfamily pathway gene expression signature in non-GI cancer
(C) Comparison of disrupted TGF-b superfamily pathway activity in GI and other c
Fold changes (x axis) were calculated from themedian log ratio of mRNA expressi
wild-type for the 43 TGF-b pathway genes) associated with mutations in GI versus
changes in GI versus other cancers. Q-values were calculated by Wilcoxon signe
adjustment.
(D) Differential expression of TGF-b superfamily pathway target genes in GI and
(E) Comparison of global transcriptional output. The ratio of TGF-b target gene ex
highest absolute mRNA expression changes (top 20 increases and top 20 decre
See also Figure S4.To compare the TGF-b pathway transcriptional signatures in
GI versus other cancers, we calculated the target gene expres-
sion signatures associated with TGF-b pathway mutations in
both groups (Figures 4A and 4B). The upregulation of TERT
and HMGA2 was less substantial in GI cancers than in the
Pan-Cancer cohort. Whereas IL6 mRNA was increased in most
non-GI cancers with TGF-b pathway mutations, IL6 upregulation
was significantly greater in GI cancers than non-GI cancers (Fig-
ure S4B), and within GI cancers, IL6 expression was greater in
samples with alterations in the TGF-b pathway genes than those
without alterations in the TGF-b pathway genes. Notably, in non-
GI cancers associated with GDF1mutations, IL6mRNA expres-
sion was markedly decreased, suggesting that GDF1 may play
different roles in GI and non-GI cancers. A similar analysis re-
vealed a profound difference in FOS expression between GI
and non-GI cancers (Figure S4C). In GI cancers, most TGF-b
pathway gene mutations were associated with increased FOS
expression; exceptions were TGFBRAP1, SMAD7, SMAD5,
GDF1, BMP5, and ACVRL1. In non-GI cancers, only mutations
in TGFBR2 were associated with increased FOS expression; all
other TGF-b pathway gene mutations were associated with
decreased FOS expression.
To compare the transcriptional output resulting frommutations
inGI and non-GI cancers, we calculated differences in expression
of the 50 target genes associated with mutations in the 43 genes
(Figure4C). Theanalysis revealedashift toward repressionof tran-
scriptional output in GI cancers, with the most significant shifts
occurring with mutations in ACVR2B, INHBA, SMAD3, or GDF2.
In GI cancers, mutations in GDF1 were associated with signifi-
cantly increased target gene transcription. We also analyzed
downregulation in each target gene (Figure 4D). Mutations in any
of the 43 genes were associated with reduced mRNA expression
in GI cancers compared with non-GI cancers for most target
genes with the largest reductions found for HMGA2 and TERT.
Compared to non-GI cancers, GI cancers had fewer genes with
increased expression resulting from pathway mutations. In GI
cancers, mutations in any of the 43 genes were associated with
a significantly increased expression of FOS, IL6, ZEB2, and
ZEB1 compared to expression changes of the same genes result-
ing from pathway mutations in non-GI cancers.
Finally, we probed for associations between transcriptional
output and TGF-b pathway gene alterations for all cancers and
the GI and non-GI subsets (Figure 4E). The top 20 and bottom
20 genes that were up- or downregulated in each case differed.
However, all 3 cases included genes associated withmetastasis,
cell adhesion, and EMT. Members of the CEACAM family,
which consists of proteins involved in pathogen sensing, innate
immunity, and metastasis (Chen et al., 2016a; Vitenshteins. Same analysis as (A) for 7,614 samples of 27 non-GI cancer types.
ancers. Volcano plots for 43 TGF-b pathway genes in GI versus other cancers.
on across 50 downstream target genes (normalized tomedian levels in samples
other cancers. Red Q-values (y axis) identify genes with statistically significant
d-rank test for each pathway gene, followed by Benjamini-Hochberg (BH) FDR
other cancers. The same as (C) but for TGF-b pathway target genes.
pression in samples with and without gene alterations. Genes listed include the
ases) in the presence of alterations of the 43 TGF-b superfamily genes.
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Figure 5. mRNA Analysis of TGF-b Superfamily Pathway Genes
(A) TGF-b superfamily pathwayactivityacrossPan-Cancer tumor types.Boxplot showing thedistributionof sample-specificpathwayscoresacross eachcancer type.
Scores were computed using mRNA transcript levels of genes in the superfamily. The median and interquartile range (boxes) and outliers (whiskers) are shown.
(B) Supervised clustering of mRNA expression. mRNA expression values for the 43 genes, clustered from left to right by tumor type, then by TGF-b superfamily
pathway score.
See also STAR Methods.et al., 2016), were consistently upregulated. TMPRSS4 and
ADAMTS19, encoding cell surface proteases, were upregulated
in the Pan-Cancer and GI cohorts, respectively. Genes that
encode immune-related proteins were also upregulated:PRAME
in the Pan-Cancer cohort and GPR31 in GI tumors.
Gene Expression Levels Quantify TGF-b Signaling
Pathway Activity
To explore TGF-b signaling pathway variation across the 33 can-
cers in the Pan-Cancer cohort, we computed a ‘‘pathway activity
score’’ based on mRNA expression of the 43 genes. We verified430 Cell Systems 7, 422–437, October 24, 2018that none of the genes were universally inhibitory in every cancer
context. We validated the pathway score by correlating it with
the median expression of the 50 TGF-b target genes and, sepa-
rately, with the median expression of 50 random genes (Fig-
ure S5) (see STAR Methods).
Patterns emerged when we grouped activity scores by tumor
type (Figure 5A). The two hematologic TCGA cancers, DLBC and
acute myeloid leukemia (LAML), had the lowest median pathway
activity scores. Uterine carcinosarcoma (UCS) had the highest
median pathway activity score (Figure 5A). Five cancers—lung
squamous cell carcinoma (LUSC), cervical squamous cell
carcinoma and endocervical adenocarcinoma (CESC), meso-
thelioma (MESO), TGCT, and kidney renal clear cell carcinoma
(KIRC)—had significant differences in overall survival between
patients with high and low pathway activity (Figure S6).
Supervised clustering of the 43 genes revealed that INHBC
and INHBE were highly expressed in LIHC, whereas BMP3 and
BMP5 were highly expressed in lung adenocarcinoma (LUAD)
(Figure 5B). GDF1 expression was high in brain cancers (glio-
blastoma multiforme [GBM] and brain lower grade glioma
[LGG]), rare cancers (UCS and pheochromocytoma and para-
ganglioma [PCPG]), and in SKCM. NODAL expression was
high in TGCT. The heatmap indicates the wide range of expres-
sion for the 43 genes in different tumor contexts and reveals po-
tential targets for further study.
Unsupervised clustering of the 43 genes produced 11 clusters
(Figure S7 and Table S5) that were dominated by cancer type.
Cluster C3 was enriched with LAML, LUSC, CESC, squamous
ESCA, head and neck squamous cell carcinoma (HNSC), and
squamous BLCA. Cluster C3 was characterized by high expres-
sion of BMP3, BMP7, SMAD3, and ACVR1C, coupled with low
expression of BMPR1B, suggesting that BMPR1B signaling
may be tumor suppressive, whereas signals involving BMP3,
BMP7, SMAD3, and ACVR1C may be tumor promoting in can-
cers enriched in that cluster. Cluster C4 was enriched with GI
cancers ESCA, STAD, COAD, and READ. Cluster C4 was char-
acterized by high expression of ACVR1C, BMP4, BMP5, and
INHBA, coupled with low expression of INHA, BMPR1B,
GDF1, INHBB, TGFB2, and TGFB3. Those observations suggest
tumor-promoting roles for the highly expressed set of genes and
tumor-suppressive roles for the set with low expression in cancer
types enriched in that cluster.
Cluster C7, which contained most of the breast cancer sam-
ples, included two subclusters that did not correspond to clinical
breast cancer subtypes (luminal A, luminal B, HER2, basal, or
normal-like). Instead, the subclusters separatedmainlyon theba-
sis of low and high levels ofBMPR1B expression. Thus, BMPR1B
signaling may have a tumor-promoting role and could be a viable
therapeutic target for at least a subset of breast cancers.
Figure 6A shows a clustered heatmap of pairwise Pearson’s
correlations between expression of the 43 TGF-b pathway genes
and expression of the 50 downstream target genes. Surprisingly,
expression of none of the 43 TGF-b pathway genes was strongly
negatively correlatedwith the activity score, including expression
of the pathway inhibitorsSMAD6/7.We attribute this observation
to co-occurring amplifications or deletions of SMAD7 and
SMAD2 and co-occurring amplifications of SMAD6 and SMAD3
(Figure 1B). Expression of ligand-encoding INHBE had the stron-
gest negative correlation with pathway activity. Within the down-
stream targets, expressionofTERT andFOXK2had the strongest
negative correlations with activity score, suggesting that their
suppression may contribute to the pathway’s tumor-suppressor
role. By contrast, expression of the EMT genes ZEB1 and ZEB2
positively correlated with pathway score, providing a possible
mechanism for the tumor-promoting effects of the pathway.
TGF-b Pathway Activity Correlates with Activity of Other
Cancer-Related Pathways
With proteomic data and a published method (Akbani et al.,
2014), we computed activity scores for 10 other oncogenic path-ways: apoptosis, breast reactive, cell cycle, hormone receptor,
hormone signaling, PI3K/AKT, RAS/MAPK, RTK, TSC/mTOR,
and DNA damage response (DDR). We assigned activity scores
for EMT and leukocyte infiltration (an index of immune function)
using mRNA and DNA methylation data, respectively (Cancer
Genome Atlas Research Network, 2017). A clustered heatmap
representation (Figure 6B) shows that the Pan-Cancer cohort ex-
hibited a negative correlation between the TGF-b superfamily
pathway score and the activity scores for the cell cycle pathway
and apoptosis pathway. In contrast, positive correlations
occurred for the EMT pathway, breast reactive pathway, RAS/
MAPK, and the RTK pathway. Table S6 shows correlations
within individual tumor types and the EMT and cell cycle
pathways.
Downstream Target Genes HMGA2, COL1A1/COL1A2/
COL3A1, and MMP9 Are Associated with Patient
Survival
We analyzed the combined impact of TGF-b target gene expres-
sion and the 43 core gene alterations on patient survival across
the Pan-Cancer cohort. We compared the survival of patients
with 3 different cancer profiles: those with high expression of
HMGA2 and alterations in any one of the 43 TGF-b pathway
genes (Figure 6C; high HMGA2/TGF-b mutant), those with high
HMGA2 expression and no alterations in any of the 43 genes (Fig-
ure 6C; high HMGA2/TGF-b wild-type), and those with low
expression of HMGA2 without considering alterations in TGF-b
pathway genes (Figure 6C; low HMGA2 expression). Patients
with low HMGA2 expression had the best outcome, followed by
patients with high expression of HMGA2 and no mutations in
the 43 genes. A similar trend was observed for genes encoding
MMP9, collagens, and to a lesser extent for FOXP3. TERT over-
expression had no impact on survival. We saw the opposite for
cancers with downregulated CDH2; the worst outcome was
associated with lowCDH2 expression andmutations in 43 genes
(Figure S6B). Thus, the expression profile of specific target genes
and alterations in the TGF-b superfamily genes cooperated to in-
crease tumor aggressiveness. The impact on survival was most
significant for overexpression of collagen-encoding genes,
HMGA2, andMMP9 (Figures 6C–6E). Because of the association
of collagen overexpression and alterations in TGF-b pathway
genes with poor survival, we hypothesize that altered signaling
through the TGF-b superfamily pathways remodels the extracel-
lular matrix to drive metastasis in multiple cancer contexts.
We analyzed survival in GI and non-GI cancers (Figure S6D). In
the GI cohort, only ZEB2 combined with TGF-b pathway gene
alteration yielded a significant difference, with low ZEB2 expres-
sion corresponding to a survival benefit. In non-GI patients, high
expression of the TGF-b pathway target genes IL6, HMGA2,
ZEB2, and FOS was associated with reduced survival, particu-
larly when combined with TGF-b pathway mutations. Thus,
although TGF-b pathway mutations may not occur as commonly
in non-GI cancers, they may be important contributors to
mortality.
Epigenetics and miRNAs Modulate TGF-b Pathway
Activity
To explore regulation of TGF-b pathway activity, we evaluated
DNA methylation (Table S6) and miRNA expression (Table S7);Cell Systems 7, 422–437, October 24, 2018 431
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Figure 6. Correlation of TGF-b Superfamily Genes with Other Cancer-Related Pathways and Genes
(A) Clustered heatmap of pairwise correlations between TGF-b pathway gene expression and that of 50 downstream target genes. Unsupervised hierarchical
clustering was conducted with 1-Pearson’s correlation distance metric and Ward’s linkage. The covariate bar on each axis shows median expression values.
(B) Clustered heatmap of correlations between TGF-b pathway activity score and 12 other cancer-associated pathways. Oncogenic pathway activity scores
(y axis) were computed from protein data, except for EMT (mRNA) and immune scores (DNA methylation).
(C) Impact of TGF-b pathway-associated HMGA2 mRNA expression on patient survival. 10-year survival of patients with TGF-b pathway mutations (TGF-b
mutant) and highHMGA2 expression (High HMGA2), no mutations in the TGF-b pathway genes (TGF-bwild-type) and highHMGA2 expression, and lowHMGA2
expression (regardless of mutation status of 43 genes) was compared in a Kaplan-Meier analysis. Statistical significance was assessed by log-rank test (see
STAR Methods and Figure S6 for selection of high and low expression level thresholds).
(D) Impact of collagen-encoding gene (COL1A1, COL1A2, COL3A1) mRNA expression on patient survival. The same analysis as in (C) was performed for
aggregated mRNA expression of three collagen genes that showed increased expression in cancers with TGF-b pathway gene mutations.
(E) Impact of MMP9mRNA expression on patient survival. The same analysis as in (C) was performed for the impact ofMMP9 expression on patient survival by
comparing high MMP9/TGF-b pathway mutations, high MMP9/wild-type TGF-b pathway, and low MMP9.
See also Figures S5 and S6 and Table S6.both processes are associated with cancer (Dawson and Kou-
zarides, 2012; Jones and Baylin, 2007; Shen and Laird, 2013).
Methylation levels across the 41 genes for each sample grouped
by tumor type revealed a high variability (Figure 7A). Despite this
variability, when ordered by TGF-b pathway activity, DLBCs with432 Cell Systems 7, 422–437, October 24, 2018the lowest TGF-b pathway activity score had the highest median
and range of DNA methylation scores, and LAML with low
pathway activity had a low median DNA methylation score (Fig-
ure 7A). Hence, epigenetic silencing appeared to contribute to
low pathway activity in DLBC but not LAML. UCSs with the
Figure 7. Epigenetic Control of the TGF-b Superfamily Pathways
(A) Methylation levels. Boxes quantify the degree of methylation across the 43 TGF-b genes in a given tumor type. The methylation score is calculated from the
median for each gene in a given sample. Scores are grouped by tumor type. The median and interquartile range (boxes) and outliers (whiskers) are shown.
(B) Supervised cluster analysis of methylation patterns. Methylation patterns were clustered as in Figure 6A. Methylation levels were quantified as M-values by
firstmappingmethylation array probes to individual genes. Amedian beta value for each genewas then calculated as themedian beta value across all samples for
a given cancer type.
(C)microRNA levels. Boxplot showing themeanmiRNA expression levels for the 32miRNAs that regulate the indicated genes in the TGF-b superfamily pathways.
The median and interquartile range (boxes) and outliers (whiskers) are shown.
(D) microRNA regulation. Inferred miR-mRNA targeting for 15 TGF-b superfamily pathway genes by the 32 miRNAs.
(E) Abundance of miRNAs predicted to target the TGF-b superfamily pathway genes. The heatmap illustrates miRNA abundance for 8,930 tumor samples from 32
of the 33 TCGA tumors (GBM excluded, no miRNA data in TCGA).
(F) Contribution of data type to TGF-b superfamily pathways score. Tumor types (columns) ordered from lowest (left) to highest (right) TGF-b superfamily pathway
score. MeanmiRNA expression levels normalized between 0 and 1 yielded the highest overall correlation with pathway score (R =0.68). Mean DNAmethylation
beta values normalized between 0 and 1 had the next highest correlation (R = 0.46). Amplifications (R = 0.24), deletions (R = 0.09), and mutations (R = -0.05)
represent proportions of samples with the given type of aberration in at least one of the 43 TGF-b genes.
See also Figure S7 and Tables S5, S6, and S7.highest TGF-b pathway activity score had a low median methyl-
ation score, suggesting that other mechanisms contribute to the
differences in activity scores.
We clustered DNA methylation levels (supervised by cancer
type) (Figure 7B) and compared the results with supervised clus-
tering of the expression of the 43 TGF-b pathway genes (Fig-
ure 5B). The epigenetic cluster analysis divided the genes into
two main groups: those with little or no DNA methylation in any
cancer and those with DNA methylation in some or all cancers.
The cluster with high DNA methylation scores included
SMAD9, SPTBN1, ACVRL1, GDF2, INHBC, INHBE, INHBA,and TGFB3. The presence of ACV ligands suggested that those
ligands are tumor suppressive in many cancers. Adaptor
SPTBN1 had a high DNA methylation score in all cancer sam-
ples, supporting a tumor-suppressive role.
We focused on miRNAs that, according to miRBase (Kozo-
mara and Griffiths-Jones, 2014), are associated with the 43
TGF-b pathway genes. We selected the top 32 miRNAs anti-
correlated with transcript abundance (Table S7). Those miRNAs
exhibited variable expression across the 32 tumor types (Fig-
ure 7C; GBM had no miRNA data). LAMLs with low TGF-b
pathway activity had the highest level of miRNA expression,Cell Systems 7, 422–437, October 24, 2018 433
suggesting that miRNAs regulate pathway activity in this blood
cancer.
We predicted that 15 of the 43 genes were targets of at least 1
miRNA; BMPR2, TGFBR2, and SMAD4 were each targeted by 5
or more miRNAs (Figure 7D). An miRNA/mRNA topology map for
the GI cancers (COAD, READ, STAD, ESCA, LIHC, and PAAD)
(Figure S7B) revealed thatBMP3was targeted only in GI cancers
and that SMAD4 was targeted only in the Pan-Cancer cohort,
suggesting that miRNA/mRNA topologies depend on tumor
context.
Cluster analysis (supervised by cancer type) yielded an inter-
esting pattern for miRNA 92a-3p, which is predicted to target
the 3 core genes BMPR2, TGFBR2, and SMAD7. miRNA 92a-
3p was overexpressed in breast, ovarian, liver, and head and
neck cancers. We also identified BMPR2 and TGFBR2 as genes
with hotspot sites of mutations that were common in STAD and
COAD. The cancers with high frequencies of hotspot mutations
in those two genes did not have high expression of miRNA
92a-3p, suggesting that there is little selective pressure for
both mutation and downregulation by that miRNA. To examine
the contribution of mutations, amplifications, deletions, DNA
methylation, and miRNAs to the pathway activity score across
tumor types, we computed Pearson’s correlations between the
pathway activity score and (1) levels of DNA methylation or
miRNA expression and (2) percentages of mutations or CNVs
in each tumor type and plotted the results in order of increasing
pathway activity scores (Figure 7F). The results suggested that
miRNAs play a dominant role in LAML, DLBC, uveal melanoma
(UVM), and THYM, all of which had low TGF-b pathway activity
scores. DNA methylation was dominant in DLBC, STAD, breast
invasive carcinoma (BRCA), andCOAD. Amplifications positively
correlated with the activity score and played a dominant role in
UCS, sarcoma (SARC), ESCA, cholangiocarcinoma (CHOL),
and ovarian serous cystadenocarcinoma (OV). However, OV
has a high background CNV burden, making it difficult to distin-
guish functionally important effects from passenger alterations.
Overall, deletions exhibited a low positive correlation with the
pathway activity score, and mutations showed the weakest
correlation.
DISCUSSION
Because TGF-b superfamily signaling plays context-dependent
roles as both a tumor suppressor and tumor promoter, TGF-b
biological function is notably ambiguous. However, given its
prominent role in cancer, understanding its function in diverse
settings will be necessary to design therapy for tumors with
aberrant TGF-b signaling. Hence, this study focused on
elucidating salient characteristics of TGF-b-associated genes
across a large cohort of different types of cancers. Some of
the key findings of the study were that (1) 39% of the cancers
carried TGF-b pathway gene alterations; (2) the genomic alter-
ations appeared to affect expression of metastatic and EMT
genes; (3) 6 hotspot mutations were identified in 6 genes; (4)
the pathway was most frequently aberrant in GI cancers, which
exhibited 115 of the 176 hotspot mutations identified; (5) high
expression of downstream target genes coupled with mutations
in the TGF-b pathway genes was associated with poor
outcome, suggesting a net tumor-promoting role of the super-434 Cell Systems 7, 422–437, October 24, 2018family across the Pan-Cancer cohort; (6) apparent gene
silencing by DNA methylation and deletion of TGF-b pathway
genes were observed most frequently in DLBC, whereas miRNA
silencing was seen most often in LAML. DLBC and LAML also
had the lowest TGF-b pathway activity scores, suggesting a
possible tumor-suppressive role of the TGF-b superfamily in he-
matologic cancers.
Although 39% of the cancers had genomic alterations in at
least one of the TGF-b pathway genes, GI cancers were particu-
larly enriched for them. GI cancers were most influenced by
recurrent hotspot mutations in 6 genes, SMAD4, SMAD2,
BMPR2, BMP5, TGFBR2, and ACVR2A. The hotspot mutations
in BMP5 and TGFBR2 had not been identified previously, and
their function in GI cancer should be explored.
UCS showed the highest TGF-b superfamily pathway activity.
High activity was associated with amplifications or low DNA
methylation. In general, epigenetics appeared to play a strong
role in regulating the activity of the TGF-b superfamily pathways
in DLBC, COAD, BRCA, STAD, and LUAD, whereas miRNAs
played a strong role in LAML, UVM, and THYM. Such cancer
type-dependent differences in the regulation of the TGF-b
pathway could prove important to the development of therapies
that target the pathway.
TGF-b signaling pathway activity correlated positively with
other cancer-relevant pathways, including EMT, breast reac-
tive, RAS/MAPK, and RTK pathways. Conversely, activity of
the TGF-b pathways was anti-correlated with the cell cycle
and apoptosis pathways. Overall, this study provides a molec-
ular portrait of genetics, epigenetics, and miRNA-mediated
regulation of signaling mediated by the TGF-b superfamily.
We expect that this body of organized data and information
will be mined by other researchers over time to formulate,
test, or validate a variety of additional hypotheses that have
not yet come into focus.STAR+METHODS
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terminants of Smad function in TGF-beta signaling. Trends Biochem. Sci.
40, 296–308.
McCarroll, S.A., Kuruvilla, F.G., Korn, J.M., Cawley, S., Nemesh, J., Wysoker,
A., Shapero, M.H., de Bakker, P.I., Maller, J.B., Kirby, A., et al. (2008).
Integrated detection and population-genetic analysis of SNPs and copy num-
ber variation. Nat. Genet. 40, 1166–1174.
McPherson, A., Hormozdiari, F., Zayed, A., Giuliany, R., Ha, G., Sun, M.G.,
Griffith, M., Heravi Moussavi, A., Senz, J., Melnyk, N., et al. (2011). deFuse:
an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS
Comput. Biol. 7, e1001138.
Mermel, C.H., Schumacher, S.E., Hill, B., Meyerson, M.L., Beroukhim, R., and
Getz, G. (2011). GISTIC2.0 facilitates sensitive and confident localization of the
targets of focal somatic copy-number alteration in human cancers. Genome
Biol. 12, R41.
Mishra, L., Derynck, R., and Mishra, B. (2005). Transforming growth factor-
beta signaling in stem cells and cancer. Science 310, 68–71.
Morishita, A., Zaidi, M.R., Mitoro, A., Sankarasharma, D., Szabolcs, M.,
Okada, Y., D’Armiento, J., and Chada, K. (2013). HMGA2 is a driver of tumor
metastasis. Cancer Res. 73, 4289–4299.
Moustakas, A., and Heldin, C.H. (2016). Mechanisms of TGFbeta-induced
epithelial-mesenchymal transition. J. Clin. Med. 5, https://doi.org/10.3390/
jcm5070063.
Muraoka-Cook, R.S., Kurokawa, H., Koh, Y., Forbes, J.T., Roebuck, L.R.,
Barcellos-Hoff, M.H., Moody, S.E., Chodosh, L.A., and Arteaga, C.L. (2004).
Conditional overexpression of active transforming growth factor beta1 in vivo
accelerates metastases of transgenic mammary tumors. Cancer Res. 64,
9002–9011.
Olshen, A.B., Venkatraman, E.S., Lucito, R., and Wigler, M. (2004). Circular bi-
nary segmentation for the analysis of array-based DNA copy number data.
Biostatistics 5, 557–572.
Park, S.W., Hur, S.Y., Yoo, N.J., and Lee, S.H. (2010). Somatic frameshift mu-
tations of bone morphogenic protein receptor 2 gene in gastric and colorectal
cancers with microsatellite instability. APMIS 118, 824–829.
Principe, D.R., Doll, J.A., Bauer, J., Jung, B., Munshi, H.G., Bartholin, L.,
Pasche, B., Lee, C., and Grippo, P.J. (2014). TGF-b: duality of function be-
tween tumor prevention and carcinogenesis. J. Natl. Cancer Inst. 106, djt369.
Radenbaugh, A.J., Ma, S., Ewing, A., Stuart, J.M., Collisson, E.A., Zhu, J., and
Haussler, D. (2014). RADIA: RNA and DNA integrated analysis for somatic mu-
tation detection. PLoS One 9, e111516.
Ramos, A.H., Lichtenstein, L., Gupta, M., Lawrence, M.S., Pugh, T.J.,
Saksena, G., Meyerson, M., and Getz, G. (2015). Oncotator: cancer variant
annotation tool. Hum. Mutat. 36, E2423–E2429.
Ratan, A., Olson, T.L., Loughran, T.P., Jr., and Miller, W. (2015). Identification
of indels in next-generation sequencing data. BMC Bioinformatics 16, 42.
Reich, M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., and Mesirov, J.P.
(2006). GenePattern 2.0. Nat. Genet. 38, 500–501.
Robertson, G., Schein, J., Chiu, R., Corbett, R., Field, M., Jackman, S.D.,
Mungall, K., Lee, S., Okada, H.M., Qian, J.Q., et al. (2010). De novo assembly
and analysis of RNA-seq data. Nat. Methods 7, 909–912.
Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B.S., and Swanton, C.
(2016). DeconstructSigs: delineating mutational processes in single tumors
distinguishes DNA repair deficiencies and patterns of carcinoma evolution.
Genome Biol. 17, 31.
Rossi, M.R., Ionov, Y., Bakin, A.V., and Cowell, J.K. (2005). Truncating muta-
tions in the ACVR2 gene attenuates activin signaling in prostate cancer cells.
Cancer Genet. Cytogenet. 163, 123–129.
Mehrvarz Sarshekeh, A.M., Advani, S., Overman,M.J., Manyam, G., Kee, B.K.,
Fogelman, D.R., Dasari, A., Raghav, K., Vilar, E., Manuel, S., et al. (2017).
Association of SMAD4 mutation with patient demographics, tumor character-
istics, and clinical outcomes in colorectal cancer. PLoS One 12, e0173345.
Saunders, C.T., Wong, W.S., Swamy, S., Becq, J., Murray, L.J., and
Cheetham, R.K. (2012). Strelka: accurate somatic small-variant calling from
sequenced tumor-normal sample pairs. Bioinformatics 28, 1811–1817.
Seoane, J., and Gomis, R.R. (2017). TGF-beta family signaling in tumor sup-
pression and cancer progression. Cold Spring Harb. Perspect. Biol. 9,
https://doi.org/10.1101/cshperspect.a022277.
Shabalin, A.A. (2012). Matrix eQTL: ultra fast eQTL analysis via largematrix op-
erations. Bioinformatics 28, 1353–1358.
Shen, H., and Laird, P.W. (2013). Interplay between the cancer genome and
epigenome. Cell 153, 38–55.
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Subject Details
Human Data, Tumor Data and TGF-b Pathway Gene Selection
Molecular data were obtained from patients that had not received prior treatment for their disease (ablation, chemotherapy, or radi-
ation therapy) and had provided informed consent as part of The Cancer Genome Atlas Project (TCGA). Local Institutional Review
Boards (IRBs) at the tissue source sites reviewed protocols to approve submission of cases.
We selected samples from 33 TCGA projects to analyze the genomic, epigenomic and transcriptomic alterations in the TGF-b
pathway.
TCGA Project Management collected necessary human subjects documentation to ensure the project complies with 45-CFR-46
(the ‘‘Common Rule’’). The program has obtained documentation from every contributing clinical site to verify that IRB approval has
been obtained to participate in TCGA. Such documented approval may include one or more of the following:
d An IRB-approved protocol with Informed Consent specific to TCGA or a substantially similar program. In the latter case, if the
protocol was not TCGA-specific, the clinical site PI provided a further finding from the IRB that the already-approved protocol is
sufficient to participate in TCGA.
d A TCGA-specific IRB waiver has been granted.
d A TCGA-specific letter that the IRB considers one of the exemptions in 45-CFR-46 applicable. The two most common exemp-
tions cited were that the research falls under 46.102(f)(2) or 46.101(b)(4). Both exempt requirements for informed consent,
because the received data and material do not contain directly identifiable private information.
d A TCGA-specific letter that the IRB does not consider the use of these data and materials to be human subjects research. This
was most common for collections in which the donors were deceased.Cell Systems 7, 422–437.e1–e7, October 24, 2018 e2
METHOD DETAILS
Sample Processing
Cases were staged according to the American Joint Committee on Cancer (AJCC). Each frozen primary tumor specimen had a com-
panion normal tissue specimen (blood or blood components, including DNA extracted at the tissue source site). Adjacent tissue was
submitted for some cases. Specimens were shipped overnight using a cryoport that maintained an average temperature of less
than 180C.
RNA and DNA were extracted from tumor and adjacent normal tissue specimens using a modification of the DNA/RNA AllPrep kit
(Qiagen). The flow-through from the Qiagen DNA column was processed using a mirVana miRNA Isolation Kit (Ambion). This latter
step generated RNA preparations that included RNA <200 nt suitable for miRNA analysis. DNA was extracted from blood using the
QiaAmp blood midi kit (Qiagen). Each specimen was quantified by measuring Abs260 with a UV spectrophotometer or by PicoGreen
assay. DNA specimens were resolved by 1% agarose gel electrophoresis to confirm high molecular weight fragments. A custom
Sequenom SNP panel or the AmpFISTR Identifier (Applied Biosystems) was utilized to verify tumor DNA and germline DNA were
derived from the same patient. Five hundred nanograms of each tumor and normal DNA were sent to Qiagen for REPLI-g whole
genome amplification using a 100 mg reaction scale. Only specimens yielding a minimum of 6.9 mg of tumor DNA, 5.15 mg RNA,
and 4.9 mg of germline DNA were included in this study. RNA was analyzed via the RNA6000 nano assay (Agilent) for determination
of an RNA Integrity Number (RIN), and only the cases with RIN >7.0 were included in this study. Reasons for rejection are described at
https://tcga-data.nci.nih.gov/datareports.
Selection of 43 Core Genes Associated with the TGF-b Superfamily
We selected the list of core TGF-b superfamily genes used in the paper by searching for the keyword ‘‘TGF-b’’ in 4 databases: (i)
BIOCARTA_TGFB_PATHWAY from GSEA (http://software.broadinstitute.org/gsea/msigdb/cards/BIOCARTA_TGFB_PATHWAY),
(ii) KEGG_TGF_BETA_SIGNALING_PATHWAY from GSEA (http://software.broadinstitute.org/gsea/msigdb/cards/KEGG_TGF_
BETA_SIGNALING_PATHWAY), (iii) GO_0007179 full gene set from BioMart, and (iv) subset of GO_0007179 (filtered by "experi-
mental evidence") from AmiGo. The union of the resulting lists comprised 181 genes. We then filtered the list down to 43 genes using
the following three criteria. (i) Based on the databases’ annotations and prior literature, the genes were divided into two categories:
those belonging to the signaling cascades and those that encoded targets of the signaling cascades.We retained genes in the former
category. (ii) We then performed extensive literature searches and kept only those genes that satisfied any of the following conditions:
(a) the gene had previously been implicated in cancer, or (b) the gene was involved in direct binding to and regulation of Smad func-
tion, or (c) the genewas phenotypically associated with the TGF-b superfamily, wheremutations or deletions of the gene had resulted
in phenotypes similar to those from loss of function of the TGF-b superfamily pathways. (iii) Finally, we discussed the complete list of
181 genes and the results of our literature searches with subject matter experts in the TCGA consortium and, after recommendations,
reached a consensus for manual curation.
That selection process resulted in 43 ‘‘core’’ genes, including 2 genes encoding adaptor proteins (SPTNB1 and ZFYVE9) that are
important in TGF-b signaling and genetically associated by phenotype (Table S1A). However, those two genes are not exclusive to
the TGF-b superfamily and they play roles in other cellular processes as well. The other 41 core genes encode components of each
level of the ‘‘canonical’’ TGF-b signaling pathway that activates Smads to regulate gene expression (Figure 1A). Other genes that are
not members of the canonical pathway (the ‘‘noncanonical’’ TGF-b signaling pathway) are not included in the set of 43 genes, but
noncanonical signaling is represented in Figure S1A for the sake of completeness. The 43 genes used in the study encode 3 ligands
in the TGF-b subfamily, 8 ligands in the BMP (bone morphogenetic protein) subfamily, and 9 ligands in the ACV (activin) subfamily;
3 receptors for the TGF-b subfamily and 1 interacting protein (TGFBRAP1), 3 receptors for the BMP family, and 6 receptors for the
ACV family; and 8 Smads (receptor-activated R-Smads, inhibitor I-Smads, and the commonCo-Smad). The list of 43 genes has been
made available at cBioPortal (http://www.cbioportal.org) under the category, ‘‘General: TGF-b superfamily,’’ so users can explore
them further and/or add their own selected genes to study alongside the gene set we used.
Similarly, 50 downstream genes were selected to study transcriptional output of TGF-b pathway activity. These genes included
proteins that function in association with TGF-b pathways (2), proteins that regulate the extracellular matrix (2), extracellular matrix
proteins (3), transcription factors (13), apoptosis regulators (9), EMT regulators (10), fibrosis inducers (4), tumor promoters (4), E3 li-
gases (2), and stemness markers (1) (Table S1B).
QUANTIFICATION AND STATISTICAL ANALYSIS
Mitigation of Batch Effects and Systematic Biases
We investigated batch effects first within individual disease types, and then across tumor types. Specifically, we investigated the ef-
fects of multiple confounding factors, including differences in: (i) batches in which the samples were processed, (ii) tissue source sites
from where the samples were obtained, (iii) the date on which the samples were shipped to the data generation centers, (iv) the in-
strument on which the samples were processed, (v) the centers that generated the data. The results from individual tumor type an-
alyses can be found online at: (http://bioinformatics.mdanderson.org/tcgambatch/). We assessed the magnitude of batch effects
using the following algorithms, (i) clustered heat maps, (ii) PCA plots, and (iii) box plots. Whenever batch effects were observed,
we corrected them using (i) ComBat (Johnson et al., 2007), or an enhanced version of it, (ii) Replicates Based Normalizatione3 Cell Systems 7, 422–437.e1–e7, October 24, 2018
(RBN) (Akbani et al., 2014), or (iii) removal of bad gene/probe data. Using those methods, we corrected the mRNA, miRNA, DNA
methylation and protein expression data. The mutations and copy number data were already discretized and corrected for back-
ground loads.
Differences in tumor purity were adjusted for in genomic and epigenomic data. Tumor purity differences in the expression plat-
forms, however, was completely confounded with tumor type differences. More than 5 normal samples were available for only 15
of the 33 tumor types, so application of deconvolution algorithms to the entire cohort was not possible. We acknowledge that differ-
ences in tumor purity is a limitation of TCGA expression data, however, TCGA had ensured that all their samples had high tumor con-
tent in the sample acquisition phase. The mutation calls used in all of our analyses were somatic mutations only, not germline, so
tumor purity differences had minimal impact on that data type. Copy-number alterations (CNA) were assessed as deviations in
the tumor sample from the paired normal tissue sample, so they only reflected somatic changes. However, the amplitude of CNA
signals can be suppressed in tumor samples with normal cell contamination. We thus utilized ABSOLUTE-derived tumor purity
and ploidy estimates for In Silico Admixture Removal (ISAR) of the segmentation data (Zack et al., 2013) in order to correct for
any signal dampening that may have occurred before proceeding to analyze somatic copy number alterations. To minimize the in-
fluence of normal tissue contamination and leukocytes infiltration in DNA methylation data, we chose probes not methylated in all
relevant normal tissues and blood cells, to get rid of methylation signals from possible confounding factors.
DNA Sequencing Data
Exome capture was performed using Agilent SureSelect Human All Exon 50Mb according to themanufacturer’s instructions. Briefly,
0.5–3 micrograms of DNA from each sample were used to prepare the sequencing library through shearing of the DNA followed by
ligation of sequencing adaptors. All whole exome (WES) and whole genome (WGS) sequencing was performed on the Illumina HiSeq
platform. Paired-end sequencing (2 x 101 bp forWGS and 2 x 76 bp forWE) was carried out using HiSeq sequencing instruments; the
resulting data was analyzed with the current Illumina pipeline. Basic alignment and sequence QC was done on the Picard and Fire-
hose pipelines at the Broad Institute. Sequencing data were processed using two consecutive pipelines:
(1) Sequencing data processing pipeline (‘‘Picard pipeline’’)
Picard (http://picard.sourceforge.net/) uses the reads and qualities produced by the Illumina software for all lanes and libraries
generated for a single sample (either tumor or normal) and produces a single BAM file (http://samtools.sourceforge.net/SAM1.
pdf) representing the sample. The final BAM file stores all reads and calibrated qualities along with their alignments to the genome.
(2) Cancer genome analysis pipeline (‘‘Firehose pipeline’’)
Firehose (http://www.broadinstitute.org/cancer/cga/Firehose) takes the BAM files for the tumor and patient- matched normal
samples and performs analyses including quality control, local realignment, mutation calling, small insertion and deletion identifica-
tion, rearrangement detection, coverage calculations and others as described briefly below. The pipeline represents a set of tools for
analyzing massively parallel sequencing data for both tumor DNA samples and their patient-matched normal DNA samples. Firehose
uses GenePattern (Reich et al., 2006) as its execution engine for pipelines and modules based on input files specified by Firehose.
The pipeline contains the following steps:
a. Quality control
This step confirms identity of individual tumor and normal to avoidmix-ups between tumor and normal data for the same individual.
b. Local realignment of reads
This step realigns reads at sites that potentially harbor small insertions or deletions in either the tumor or the matched normal, to
decrease the number of false positive single nucleotide variations caused by misaligned reads.
c. Identification of somatic single nucleotide variations (SSNVs)
This step detects candidate SSNVs using a statistical analysis of the bases and qualities in the tumor and normal BAMs, using
Mutect (Cibulskis et al., 2013).
d. Identification of somatic small insertions and deletions
In this step, putative somatic events were first identified within the tumor BAM file and then filtered out using the corresponding
normal data, using Indellocator (Ratan et al., 2015).
Mutation Analysis
The non-silent mutation frequencies for each gene in the individual cancer and Pan-Cancer settings are determined through mining
the MC3 TCGA MAF file (covering n=9125 patients of the Pan-Cancer pathway analysis consortium manuscript freeze sample set)
from 33 cancer types. To include only the non-silent mutations, the variant classes, ‘‘Silent,’’ "Intron,’’ "3’UTR," "3’Flank," ‘‘5’UTR,’’Cell Systems 7, 422–437.e1–e7, October 24, 2018 e4
‘‘5’Flank,’’ "IGR,’’ and "RNA" are excluded from the analyses. The oncoprints are generated using the cBioPortal oncoprinter suite.
Each oncoprint visualizes and quantifies the somatic mutation and copy number events in 9,125 patients with 33 cancer types for
each gene family in the pathway (Figure 1B). The hotspot mutations are extracted from MC3 MAF file first programmatically for
any hotspot site with more than nine counts and validated through a systematic mining in cBioPortal (Figure 3). The hotspots are
visualized using the mutationMapper tool in cBioPortal. For ACVR2A and SMAD4 hotspot mutations are mapped onto the respective
protein structures (PDB IDs: 4ASX for ACVR2A and 1DD1 for SMAD4) using the UCSF chimera software. The driver mutations in the
pathway are detected using MutSigCV for all cancer types in the Pan-Cancer set (Figures 2, 4, and 7F). Although MutSigCV is a well-
established method for detecting driver genomic aberrations in cancer, it does have the following limitations. MutSigCV is insensitive
to some genomic events, such as the co-occurrence of mutations in genomic proximity and or mutations that are associated with
transcription-coupled repair. MutSigCV identifies genomic heterogeneity across patient cohorts. Another challenge that cannot
be addressed by MutSigCV is intratumor heterogeneity and detection of driver mutations within subclones of a single tumor. Finally,
success of MutSigCV depends on the statistical properties and size of the patient population under study as the algorithm fails to
classify rare variants seen within small to mid-sized patient cohorts. Differential mRNA expression of 50 TGF-b pathway target genes
is also quantified in relation to 6 hotspot mutations in the Pan-Cancer cohort and GI cancers (Figure 3B). Rows and columns were
clustered using the complete-linkage algorithm with Euclidean distance, and dendrogram branches were ordered to minimize the
differences between the cube of the mean of adjacent rows and columns.
Copy Number Analysis
Tumor sample DNAwas extracted and hybridized to Affymetrix SNP6.0 arrays by theGenomeAnalysis Platform at the Broad Institute
as previously described (McCarroll et al., 2008). The calculated array probe intensities were normalized and combined using
SNPFileCreator (Li and Hung Wong, 2001) and then processed with Birdseed (Korn et al., 2008) to yield preliminary copy-number
estimates. Segmented relative copy-number profiles were produced by refining and partitioning the preliminary copy-number esti-
mates with tangent normalization and Circular Binary Segmentation (Olshen et al., 2004). The segmented relative copy-number pro-
files for 9,125 samples were selected for further analysis. For each disease type, GISTIC2.0 (Mermel et al., 2011) was ran on the cor-
responding copy-number profiles to identify regions undergoing significant focal-level and broad-level somatic copy-number
aberrations and to obtain gene-level estimates of copy-number. The significant genomic amplification lesions and genomic deletion
lesions identified by GISTIC2.0 were examined to determine if any TGF-b network genes were being targeted as potential oncogenic
or anti-oncogenic drivers, and the frequency of amplifications and deletions across the TGF-b network genes were computed from
the gene-level thresholded copy-number estimates (-2, -1, 0, +1, +2). Genes assigned positive values of +1 and +2 were considered
amplified, with +1 representing low-level amplification events and +2 representing high-level amplification events, and genes with
negative values of -1 and -2 were considered deleted, with -1 representing shallow deletion events and -2 representing deep deletion
events.
GISTIC2.0 is a tool for detecting independently targeted regions of SCNA, based on data-driven estimation of the background
rates of SCNA. GISTIC2.0 used data from SNP arrays, thus the successful application of GISTIC2.0 to detect low frequency differ-
ences depends on the resolution of array or sequencing platform and the population size.
GISTIC identifies somatic alterations that occur significantly more frequently than those predicted to occur at random, based on
the background rate of copy number changes. The issue with this and all significance methods is that the ability to detect rare but
meaningful driver events depends on the frequencies of their occurrence and on the number of the tumors profiled. Tumor types for
which few tumors have been profiled and that have infrequently occurring copy number alterations, GISTIC may fail to identify rare
but important somatic events. As more copy number profiles become available through large-scale tumor sequencing efforts, the
ability to detect these rare but significant events will increase.
Pathway Analysis
A pathway topology is generated to link the 43 core TGF-b pathways based on database searches in KEGG and Pathway Commons,
expert curation and literature searches. The pathway diagram is visualized and optimized for layout using the Pathway Mapper
program (Figure S4A). The genomic alteration frequencies for copy number gains or losses and mutations are extracted from the
cBioPortal and programmatically form the MC3 MAF file. The alterations are mapped to each gene in the pathway diagram. In the
GI-focused pathway analysis, only genes with >3% alteration for either copy number or mutation alterations are included in the
pathway diagram to capture only those pathways that are substantially altered (Figure S4A).
Expression Signatures of Genomic Alterations
The gene expression signatures of TGF-b pathway alterations are analyzed with a clustering algorithm. The samples with alterations
in each core gene and wild type for all TGF-b pathway genes are extracted from theMC3MAF file. The transcriptional output is quan-
tified using expression of 50 downstream genes (Figures 2G–2I). Themedian fold change of transcriptional changes are calculated as
the ratio of expression of downstream genes among all core pathway gene mutated, amplified and deleted samples to expression
levels in TGF-b pathway wild type samples. The transcriptional changes in each downstream gene vs each altered pathway gene is
analyzed and visualized with a two-way hierarchical clustered heat map (Figures 4A–4B). The hierarchical clustering is performed
using a Euclidean distance and complete linkage. The shift in the transcriptional output shift in different subsets such as Pan-Cancer
and GI cancers are visualized with a volcano plot with BH based FDR adjusted P values calculated with a Wilcoxon signed rank teste5 Cell Systems 7, 422–437.e1–e7, October 24, 2018
(null hypothesis is the transcriptional output shift in the two subsets are equal to each other) and log fold change of the fold changes in
Pan-Cancer vs. GI cancers (Figure 4C). The global transcriptional output is calculated by comparing fold changes due to TGF-b
pathway alterations in all transcripts measured (Figure 4E).
Gastrointestinal Cancers
The cancer types, Colon Adenocarcinoma (COAD, N=341), Esophageal carcinoma (ESCA, N=169), Liver hepatocellular carcinoma
(LIHC, N=348), Pancreatic adenocarcinoma (PAAD, N=152), Rectum adenocarcinoma (READ, N=118), Stomach adenocarcinoma
(STAD, N=383) are included as the gastrointestinal (GI) samples. The enrichment of TGF-b pathway genomic alterations in the GI
cancers was statistically assessed using a one tailed Fisher’s exact test, where the null hypothesis was the odds ratio of alterations
in GI vs other cancers was not greater than 1. The total number of GI samples was 1511. The transcriptional outcome of GI cancers
with TGF-b pathway disruptions were quantified using the samemethod and downstream target gene list as we did in the analysis of
transcriptional output from all cancers (Figures 3B and 4). The pathway analysis was performed as in the case of the Pan-Cancer
cohort for each GI cancer type separately (Figure S4). In the pathway analysis, the core genes with that >3% alteration frequency
for any of the alteration types (mutations, copy number amplification or deletion) were included into the pathway diagrams while
the rest was eliminated.
mRNA Expression Analysis and Pathway Activity Scores
We corrected for batch effects the TCGA mRNA data available from TCGA’s web portal (https://portal.gdc.cancer.gov/). The log2
transformed data were used for all the mRNA analysis in this project. Pathway scores were generated by first Z-normalizing the
values for the 43 core genes across all of the samples (Figures 5, 6, and 7). The mean across the 43 genes was then calculated
for each sample to yield the pathway activity score per sample. Unsupervised clustering used 1-Pearson’s correlation for the dis-
tance metric with Ward’s linkage. One limitation of the pathway activity score is that it gives equal weight to all the genes in the
pathway, meaning that the abundance of each transcript contributes an equal positive value to the score. This is not reflective of
the biology, for example, some genes encode inhibitors of pathway activity, and some components interact with multiple partners
and thus may be limiting. Another limitation is that the score uses expression of the genes as a surrogate for functional protein abun-
dance, which does not account for loss or gain of function due to mutations. Thus, the pathway activity score represents a relative
estimate not an absolute value of pathway function.
microRNA Analysis
We corrected the TCGA miRNA data available from TCGA’s web portal (https://portal.gdc.cancer.gov/) for batch effects. For 9310
primary tumor samples, we used MatrixEQTL v2.1.1 or v2.2 (Shabalin, 2012 Pubmed: 22492648) in R 3.4.1 or 3.4.4 to calculate
Spearman correlations between batch-corrected, normalized expression data for miRNA mature strands and gene-level mRNA
data for 43 pathway genes. We then filtered by records in miRTarBase v6.0 (Chou et al., 2016), retaining both stronger and weaker
functional interactions. We further filtered by requiring correlations to have a coefficient <-0.25 and an FDR <10-6, which resulted in
the retention of 40 miR-mRNA pairs involving 32 miRNA mature strands. For heat maps, we removed eight mature strands, because
they were too weakly expressed (<10 RPM) in all or most tumor types, retaining 24 mature strands. For the main heat map of batch-
correctedmiRNA-seq data, we identified 8930 samples from 32 of 33 tumor types that were from primary tumors, metastatic tumors,
or blood cancers. These samples were represented in the ordered heat map for messenger RNAs from the pathway (Figure 7E). We
ordered the samples to match the sample order in the messenger RNA heat map (i.e. with cancer types ordered to have increasing
mean pathway scores, and samples within a cancer type ordered to have increasing pathway scores). We generated a heat map
using the pheatmap v1.0.2 package, in R 3.4.1. We generated a similar heat map for the 1507 primary tumors present in LIHC,
COAD, READ, STAD, ESCA, and PAAD data sets. Box plots were generated using the boxplot() function in R (Figure 7C). The
data consisted of the mean miRNA value across the 24 miRNAs. A limitation of this approach is that the results are not based on
rigorous and objective thresholds for the metrics (like correlations or p values). Rather the thresholds were chosen to yield a reason-
ably small set of the most statistically significant miRNAs that were easy to evaluate and visualize for human interpretation. Other-
wise, the results would appear like the proverbial ‘‘hair ball.’’
DNA Methylation Profiles
We mapped the Illumina methylation array probes to individual genes using the Illumina Human Methylation 27k R annotation data
package. Forty-one of forty-three TGF-b pathway genes had at least one probe mapping to their promoter region. For genes with
multiple probes, median beta values were used. We then calculated median beta value for these 41 genes in each sample, and
plotted them using the boxplot function in R, grouped by cancer type (Figure 7A). For the heat maps, we calculated beta values
for each of the 41 genes of TGF-b pathway and the 33 tumor types by taking median across all samples for a given tumor. We
then plotted this data as a heat map using the Clustergram function in Matlab (Figure 7B). For the analysis of the GI methylation
data, probes were mapped to TGF-b pathway genes for GI cancers (COAD+READ, STAD, ESCA, PAAD and LIHC). Beta values
for each gene-sample pair was visualized as a heat map using the ComplexHeatmaps package, with TGF-b pathway genes clustered
using Euclidean distances andWard’s linkage. Box plots were generated using the boxplot() function in R. The data consisted of the
mean beta value across the 41 genes. This method assumes the mean beta value is reflective of the overall methylation level of the
entire pathway, which may not always hold and is a limitation of the approach.Cell Systems 7, 422–437.e1–e7, October 24, 2018 e6
Correlations of Pathway Score Vs. Bootstrapped Genes
Following the calculation of TGF-b pathway scores, the absolute value of the Pearson correlation between gene expression values
and pathway scores was calculated for all 20,310 genes where this calculation was possible. Next, 43 correlation values were
sampled with replacement from the correlation values of the 43 TGF-b pathway genes a total of 10,000 times, and each time the me-
dian sampled correlation was calculated. The same sampling procedure was also performed for the TGF-b target genes, where 50
correlation values were sampled with replacement from the correlation values of the 50 target genes, and for all genes, where 50
correlation values were sampled with replacement from the correlation values of all 20,310 genes. The distribution of the 10,000 me-
dian correlations for each of the three gene sets is shown in Figure S5. A p-value was also calculated for each group as the proportion
of median correlations for the ‘‘all genes’’ group that are greater than or equal to the median of each group.
Survival Analysis
Kaplan-Meier Survival Curves are generated for each patient sub cohort using the Survival and Survminer R packages (Figures 6C–
6E and S6B–S6D). The statistical significance of survival differences between multiple subcohorts were determined using the log-
rank test to capture relations. In order to segment the cohorts into subgroups characterized by expression levels of the TGF-b target
genes, we analyzed the distribution of target gene expression across the Pan-Cancer cohort. We particularly focused on mRNA
expression distribution of HMGA2,MMP9, collagens (COL1A1, COL1A2, COL3A1), TERT, FOXP3, CDH2 as the expression of these
genes varied significantly between TGF-b pathway mutated vs. wild type samples. For this purpose, we used the batch normalized
mRNA expression data. For each gene, the cut-off to separate low and high expressing cohorts was determined empirically based on
the distribution. For expression profiles with a unimodal distribution, we used the approximate median values. For bimodal cases, we
selected the threshold as the midpoint that separates each peak on the bimodal distribution. The mRNA expression threshold to
separate the cohorts with low vs. high target expression groups were HMGA2=5, MMP9=10, mean of collagens (COL1A1,
COL1A2, andCOL1A3) = 14, TERT=2, FOXP3=6, CDH2=8. The collagen genes are analyzed as a single entity because they showed
very strong correlation of mRNA expression with each other. The resulting thresholds divided the cohorts into three groups as TGF-b
expression, TGF-b mutant/high target expression, TGF-b wt/high target expression and low target gene expression. We merged
the TGF-b mutant/low target expression and TGF-b wt/low expression cohorts as discriminating between these sets do not inform
on the combined effect of TGF-b mutations and target expression. The survival differences between each sub cohort are analyzed
using the Survival and Survminer R packages.
DATA AND SOFTWARE AVAILABILITY
The raw data, processed data and clinical data can be found at the legacy archive of the GDC (https://portal.gdc.cancer.gov/
legacyarchive/search/f) and the PanCanAtlas publication page (https://gdc.cancer.gov/about-data/publications/pancanatlas). The
mutation data can be found here (https://gdc.cancer.gov/about-data/publications/mc3-2017). TCGA data can also be explored
through the Broad Institute FireBrowse portal (http://gdac.broadinstitute.org) and the Memorial Sloan Kettering Cancer Center
cBioPortal (http://www.cbioportal.org). Details for software availability are in the Key Resources Table.e7 Cell Systems 7, 422–437.e1–e7, October 24, 2018
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Supplementary Figure S1. Related to Figure 1. A. Signaling by the canonical vs. 
noncanonical TGF-β pathway. B. Clustered heat map of gene-gene correlations of the 
43 genes across the entire PanCancer cohort of 9125 samples. C. Statistical 
significance of the cumulative mutation frequency in the TGF-β superfamily 
pathways. A bootstrapping analysis is performed to assess the significance of the 
observed mutational frequency in the 43 genes. The null distribution is the mutation 
frequencies of 100,000 randomly selected sets of 37 genes (the number of genes in the 
TGF-β superfamily pathway gene set with > 0.5% mutation frequency and hence 
contribute to the cumulative frequency). The distribution is calculated using the 9125 
sample PanCancer cohort (same cohort used for analysis of the TGF-β superfamily 
pathway alterations). The TGF-β superfamily pathway gene set has significantly more 
mutations than a randomly selected gene set of identical size. p-value is 0.05 for the 
cumulative mutation frequency of the 37 TGF-β superfamily genes (each gene has a 
frequency of >0.5%). D. Significance of mutations in non-hypermutated samples. 
The same bootstrapping analysis is performed after excluding the hypermutator 
samples. The analysis leads to a lower mutation frequency and significance is not 
affected. E. Landscape of heterozygous (shallow) deletions in the TGF-β 
superfamily pathway genes. The oncoprints for heterozygous deletions in each gene 
across all cancer types as identified by GISTIC thresholds (>0.3) in the PanCancer 
cohort and visualized using the oncoprinter tool. Recurrent heterozygous loss is usually 
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Supplementary Figure S2. Related to Figure 2. A. Distribution of genomic alterations (mutations, high level amplifications and 
deep deletions) in the 43 TGF-β superfamily pathway genes across the 33 cancer types. B. The frequencies of copy number 
gain and highly amplified TGF-β superfamily genes. C. The frequencies of shallow (heterozygous) and deep (homozygous) 
deletions in TGF-β superfamily genes.
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Supplementary Figure S3. Related to Figure 3. A. Distribution of hotspot mutations in cancer types. 
Hotspots sites are enriched in GI cancers (red) — particularly in colorectal, stomach, and esophageal 
cancers — compared to other cancer types (blue). B. Potential hotspot sites in the TGF-β superfamily 
pathway genes. The lollipop mutation plots for TGF-β superfamily pathway genes noting individual amino 























































































Pathway analysis of genomic alterations in the TGF-β pathway






































































































































































































































































Supplementary Figure S4. Related to Figure 4. A. Pathway analysis of genomic 
alterations in TGF-β superfamily pathways in PanCancer and GI cancers. The 
topologies of the pathways are constructed through literature and expert curation. The 
pathways topologies capture the interactions between ligands, receptors, and 
intracellular proteins. The pathway diagrams are visualized using the pathway mapper 
software. Pathway layouts are constructed through a combination of automated 
optimization in the pathway mapper with default parameters and manual adjustment. 
The activin and TGF-β receptors activate the R-SMADs, SMAD2/3; the BMP receptors 
activate SMAD1/5 and SMAD8 molecules. Both parallel pathways converge on the 
coSMAD, SMAD4. The inhibitory SMADs act on both SMAD2/3 and SMAD1/5/8 to 
limit the pathway output. The frequencies of CNA and somatic mutations involving 
components of TGF-β pathways are quantified in boxes. Mutation frequencies are 
higher than CNV frequencies for virtually all of the subfamilies. Red (left box): high 
degree copy number amplifications, blue: deep deletions, red (right box): somatic 
mutations. The mutation and CNA frequencies in each GI tumor type (colorectal 
carcinoma, esophageal carcinoma, stomach adenocarcinoma, liver hepatocellular 
carcinoma, pancreatic adenocarcinoma) are quantified and mapped to the literature 
curated pathway diagrams. The non-altered (> 3%) parts are excluded from the analysis 
to visualize the sub pathways with substantially recurrent aberrations. Mutations are more 
common than CNA. Red (left box): high degree copy number amplifications, blue: deep 
deletions, red (right box): somatic mutations. B. Differential expression of IL6 in TGF-β 
pathway mutated vs. wild type samples in GI vs. non-GI cancers. C. Differential 
expression of FOS for TGF- β pathway mutated vs. wild type samples in GI and 
non-GI cancers.  














Supplementary Figure S5. Related to Figure 5. Distribution of median absolute value correlations 
of the TGF-β superfamily pathway score vs. different gene sets using bootstrapping over 10,000 
iterations. (Blue) 43 TGF-β superfamily pathway genes, (green) 50 downstream target genes, (red) 
randomly selected 50 genes from the data set of 20,310 genes. The lines show medians of the 
densities. Downstream targets have much higher absolute correlations than randomly selected 
genes, as do the core genes, providing evidence for validation of the TGF-β pathway scores. The p-
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Supplementary Figure S6. Related to 
Figures 5 and 6. Expression of select TGF-β 
pathway genes and patient survival. A. The 
box/violin plots showing the mRNA expression 
distribution of TGF-β target genes whose 
expression values are associated with TGF-β 
pathway mutations. B. The impact of TERT, 
CDH2 and FOXP3 expression in association 
with TGF-β pathway mutations on patient 
survival. C. Overall survival curves for KIRC, 
LUSC, MESO, CESC and TGCT showing 
differences in survival between TGF-β pathway 
high activity vs. low activity samples. D. Overall 
survival curves for the genes that are 
differentially regulated by TGF-β pathway 


























































ACC - (n= 76, 1%)
BLCA - (n= 399, 4%)
BRCA - (n= 981, 11%)
CESC - (n= 272, 3%)
CHOL - (n= 36, 0%)
COAD - (n= 341, 4%)
DLBC - (n= 37, 0%)
ESCA - (n= 169, 2%)
GBM - (n= 126, 1%)
HNSC - (n= 487, 5%)
KICH - (n= 65, 1%)
KIRC - (n= 352, 4%)
KIRP - (n= 271, 3%)
LAML - (n= 162, 2%)
LGG - (n= 507, 6%)
LIHC - (n= 348, 4%)
LUAD - (n= 502, 6%)
LUSC - (n= 464, 5%)
MESO - (n= 82, 1%)
OV - (n= 177, 2%)
PAAD - (n= 152, 2%)
PCPG - (n= 161, 2%)
PRAD - (n= 479, 5%)
READ - (n= 118, 1%)
SARC - (n= 229, 3%)
SKCM - (n= 363, 4%)
STAD - (n= 383, 4%)
TGCT - (n= 144, 2%)
THCA - (n= 480, 5%)
THYM - (n= 119, 1%)
UCEC - (n= 507, 6%)
UCS - (n= 56, 1%)
UVM - (n= 80, 1%)































































Supplementary Figure S7. Related to Figures 5 and 7. A. Unsupervised mRNA clusters. 
Clustered heat map of the mRNA data using the 43 TGF-β pathway genes across 33 cancer 
types. The clustered heat maps are generated using a Pearson correlation-based distance metric 
and ward linkage. Eleven clusters can be seen. The bars above the heat map visualize the 
distribution over cancer types. B. Pan-GI miRNA topology. Inferred miR-mRNA targeting for 43 
TGF-β pathway genes for 1507 Pan- GI primary tumor samples (from COAD, READ, STAD, 
ESCA, PAAD, and LIHC tumor types). Spearman correlations (R < -0.25, FDR <    10-6) shown 
were supported by miRTarBase v6.0 functional records with stronger and/or weaker evidence 
types. 
Supplementary Table S2. Related to Figures 1 and 2. Genomic alterations in each of the 43 core TGF-β 
superfamily pathway genes. The columns show numbers or percentages of samples altered using either mutations, 






















ACVR1 86 0.90% 58 0.60% 143 1.60% 79 7 0 
ACVR1B 123 1.30% 56 0.60% 179 2% 105 22 0 
ACVR1C 90 1% 55 0.60% 143 1.60% 80 13 0 
ACVR2A 205 2.20% 68 0.70% 267 2.90% 82 124 6 
ACVR2B 80 0.90% 45 0.50% 125 1.40% 72 8 0 
ACVRL1 102 1.10% 53 0.60% 155 1.70% 89 13 0 
BMP10 92 1% 36 0.40% 128 1.40% 83 11 0 
BMP15 96 1.10% 104 1.10% 200 2.20% 87 11 0 
BMP2 81 0.90% 58 0.60% 139 1.50% 66 18 0 
BMP3 109 1.20% 42 0.50% 151 1.70% 97 13 0 
BMP4 87 1% 40 0.40% 127 1.40% 82 5 1 
BMP5 160 1.80% 107 1.20% 264 2.90% 140 22 0 
BMP6 92 1% 116 1.30% 208 2.30% 86 6 1 
BMP7 97 1.10% 185 2% 281 3% 90 7 0 
BMPR1A 81 0.90% 91 1% 170 1.90% 59 25 0 
BMPR1B 82 0.90% 45 0.50% 127 1.40% 65 17 0 
BMPR2 176 1.90% 72 0.80% 242 2.70% 126 66 0 
GDF1 10 0.10% 0 0% 10 0.10% 10 0 0 
GDF11 39 0.40% 53 0.60% 92 1% 37 2 0 
GDF2 125 1.40% 66 0.70% 190 2.10% 116 11 0 
INHA 60 0.70% 62 0.70% 122 1.30% 52 8 0 
INHBA 146 1.60% 61 0.70% 206 2.30% 131 20 1 
INHBB 53 0.60% 67 0.70% 120 1.30% 51 2 0 
INHBC 55 0.60% 89 1% 143 1.60% 48 6 1 
INHBE 50 0.50% 87 1% 137 1.50% 46 5 0 
NODAL 42 0.50% 51 0.60% 93 1% 40 2 0 
SMAD1 57 0.60% 63 0.70% 118 1.30% 47 12 0 
SMAD2 107 1.20% 86 0.90% 191 2.10% 74 40 0 
SMAD3 109 1.20% 45 0.50% 152 1.70% 98 14 0 
SMAD4 256 2.80% 159 1.70% 402 4% 185 79 6 
SMAD5 51 0.60% 62 0.70% 112 1.20% 45 8 0 
SMAD6 40 0.40% 32 0.40% 72 0.80% 38 3 0 
SMAD7 42 0.50% 89 1% 130 1.40% 37 5 0 
SMAD9 87 1% 124 1.40% 211 2.30% 78 9 0 
SPTBN1 275 3% 66 0.70% 341 4% 235 53 2 
TGFB1 49 0.50% 74 0.80% 122 1.30% 39 12 1 
TGFB2 75 0.80% 194 2.10% 268 2.90% 61 16 0 
TGFB3 52 0.60% 45 0.50% 97 1.10% 39 10 3 
TGFBR1 94 1% 55 0.60% 147 1.60% 78 18 0 
TGFBR2 145 1.60% 80 0.90% 225 2.50% 106 36 5 
TGFBR3 139 1.50% 62 0.70% 198 2.20% 120 18 1 
TGFBRAP1 141 1.50% 29 0.30% 168 1.80% 124 16 1 
ZFYVE9 167 1.80% 56 0.60% 220 2.40% 147 26 0 
Supplementary Table S3. Related to Figure 2. All 33 TCGA tumor types (column 1) with abbreviation 
(column 2) showing the number (column 3) and percentage (column 4) of samples with aberrations in at 
least one of the 43 TGF-β superfamily pathway genes. The number (column 3) and percentage (column 4) of 
wild-type samples without any aberrations in those 43 genes are also shown, along with the total number of 
samples (column 5). Overall, 39% of the samples from a total of 9,125 samples had an aberration. The lowest 








Skin	Cutaneous	Melanoma	 SKCM	 253	 69.7%	 363	
Colon	adenocarcinoma	 COAD	 222	 65.1%	 341	
Esophageal	carcinoma	 ESCA	 109	 64.5%	 169	
Stomach	adenocarcinoma	 STAD	 243	 63.4%	 383	
Uterine	Corpus	Endometrial	Carcinoma	 UCEC	 295	 58.2%	 507	
Bladder	Urothelial	Carcinoma	 BLCA	 229	 57.4%	 399	
Pancreatic	adenocarcinoma	 PAAD	 87	 57.2%	 152	
Lung	squamous	cell	carcinoma	 LUSC	 264	 56.9%	 464	
Lung	adenocarcinoma	 LUAD	 284	 56.6%	 502	
Ovarian	serous	cystadenocarcinoma	 OV	 95	 53.7%	 177	
Lymphoid	Neoplasm	Diffuse	Large	B-
cell	Lymphoma	
DLBC	 19	 51.4%	 37	
Rectum	adenocarcinoma	 READ	 59	 50.0%	 118	
Sarcoma	 SARC	 114	 49.8%	 229	
Head	and	Neck	squamous	cell	
carcinoma	
HNSC	 221	 45.4%	 487	
Uterine	Carcinosarcoma	 UCS	 24	 42.9%	 56	
Liver	hepatocellular	carcinoma	 LIHC	 149	 42.8%	 348	
Cervical	squamous	cell	carcinoma	and	
endocervical	adenocarcinoma	
CESC	 105	 38.6%	 272	
Breast	invasive	carcinoma	 BRCA	 367	 37.4%	 981	
Cholangiocarcinoma	 CHOL	 13	 36.1%	 36	
Prostate	adenocarcinoma	 PRAD	 149	 31.1%	 479	
Adrenocortical	carcinoma	 ACC	 17	 22.4%	 76	
Kidney	renal	clear	cell	carcinoma	 KIRC	 77	 21.9%	 352	
Glioblastoma	multiforme	 GBM	 27	 21.4%	 126	
Brain	Lower	Grade	Glioma	 LGG	 94	 18.5%	 507	
Kidney	renal	papillary	cell	carcinoma	 KIRP	 50	 18.5%	 271	
Mesothelioma	 MESO	 15	 18.3%	 82	
Pheochromocytoma	&	Paraganglioma	 PCPG	 25	 15.5%	 161	
Thymoma	 THYM	 18	 15.1%	 119	
Acute	Myeloid	Leukemia	 LAML	 19	 11.7%	 162	
Uveal	Melanoma	 UVM	 9	 11.3%	 80	
Testicular	Germ	Cell	Tumors	 TGCT	 13	 9%	 144	
Kidney	Chromophobe	 KICH	 4	 6.2%	 65	
Thyroid	carcinoma	 THCA	 19	 4%	 480	
PanCan	(Total)	 3686	 40.4%	 9125	
Supplementary Table S5. Related to Figures 5 and S7. Contingency table showing percentage of 
samples in each tumor type vs. mRNA cluster shown in Fig. S7A. 
C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11
ACC 6.6 0.0 0.0 0.0 5.3 1.3 0.0 0.0 0.0 0.0 86.8
BLCA 12.0 6.8 13.8 1.0 55.4 3.0 1.3 0.5 0.0 1.0 5.3
BRCA 2.5 0.6 0.6 0.1 1.4 1.2 87.3 0.1 0.0 0.2 5.9
CESC 3.7 15.1 49.6 1.5 13.6 4.4 1.8 0.0 0.0 0.4 9.9
CHOL 86.1 0.0 0.0 0.0 8.3 2.8 0.0 0.0 0.0 0.0 2.8
COAD 0.0 0.0 0.9 95.3 3.5 0.0 0.3 0.0 0.0 0.0 0.0
DLBC 78.4 0.0 13.5 0.0 0.0 0.0 5.4 0.0 0.0 0.0 2.7
ESCA 2.4 18.9 30.8 37.9 7.1 0.6 1.8 0.6 0.0 0.0 0.0
GBM 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 96.0 0.0 4.0
HNSC 2.1 61.2 33.1 0.6 0.8 0.0 0.2 0.0 0.0 0.0 2.1
KICH 13.8 0.0 0.0 0.0 1.5 72.3 0.0 0.0 0.0 1.5 10.8
KIRC 90.6 0.0 0.0 0.6 2.0 2.3 0.3 0.0 0.0 0.0 4.3
KIRP 92.3 0.4 1.1 0.4 3.7 0.4 0.0 0.4 0.0 0.4 1.1
LAML 1.2 0.0 98.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
LGG 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 99.6 0.2 0.0
LIHC 98.6 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.3 0.9
LUAD 2.2 0.4 4.8 1.2 81.7 4.6 1.0 0.0 0.0 0.2 4.0
LUSC 2.6 8.6 71.6 0.2 5.2 3.7 1.5 0.0 0.0 0.9 5.8
MESO 4.9 1.2 1.2 0.0 75.6 0.0 2.4 0.0 0.0 0.0 14.6
OV 0.0 0.6 1.1 0.0 0.6 10.7 2.3 0.0 0.0 0.0 84.7
PAAD 3.3 0.7 0.0 4.6 87.5 0.0 2.6 0.0 0.0 0.0 1.3
PCPG 0.0 0.0 0.6 0.0 1.2 4.3 0.0 0.0 0.0 1.9 91.9
PRAD 0.0 0.0 0.0 0.0 0.2 98.7 0.0 0.0 0.0 0.0 1.0
READ 0.0 0.0 0.8 95.8 3.4 0.0 0.0 0.0 0.0 0.0 0.0
SARC 42.4 1.7 2.2 0.9 6.1 1.7 0.4 0.0 0.0 2.2 42.4
SKCM 6.1 0.0 0.0 0.0 1.1 0.6 2.5 0.0 0.0 87.9 1.9
STAD 1.0 0.5 1.6 58.7 34.2 0.3 0.8 1.3 0.0 0.8 0.8
TGCT 0.0 0.0 0.0 0.7 0.0 0.7 0.0 0.0 0.7 0.0 97.9
THCA 3.3 0.0 1.0 0.0 0.0 0.0 0.0 95.0 0.0 0.0 0.6
THYM 3.4 0.0 3.4 0.0 0.0 2.5 0.8 4.2 0.0 1.7 84.0
UCEC 1.2 0.0 3.4 0.2 2.6 43.0 0.6 0.2 0.2 0.8 47.9
UCS 0.0 0.0 0.0 0.0 1.8 1.8 1.8 0.0 0.0 0.0 94.6
UVM 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0 0.0
Supplementary Table S6. Related to Figures 6 and 7. The association of TGF-β pathway activity 
with other key pathways and biological processes and median DNA methylation beta values across 
the 43 genes of TGF-β pathway and all the samples in each tumor type.  
Tumor Type 
R values for Cancer types 
Median DNA 
Methylation Beta 
Positively correlated with 
EMT pathway 
(t-test p<0.001) 
Negatively correlated with 
Cell Cycle Pathway 
(t-test p<0.001) 
ACC 0.069 
BLCA 0.24 -0.2 0.077 
BRCA 0.49 -0.25 0.099 
CESC 0.44 0.086 
CHOL 0.098 
COAD 0.46 -0.29 0.103 
DLBC 0.228 
ESCA 0.49 0.085 
GBM 0.071 
HNSC 0.49 -0.25 0.093 
KICH 0.075 
KIRC 0.28 0.087 
KIRP 0.25 0.071 
LAML 0.084 
LGG 0.09 
LIHC 0.38 0.09 
LUAD 0.33 -0.19 0.121 
LUSC 0.44 0.084 
MESO 0.082 
OV 0.057 
PAAD 0.49 0.09 
PCPG 0.37 0.065 
PRAD 0.59 0.07 
READ 0.46 -0.35 0.086 
SARC 0.073 
SKCM 0.37 -0.26 0.093 
STAD 0.49 -0.37 0.121 
TGCT 0.56 -0.42 0.08 
THCA 0.28 -0.25 0.072 
THYM -0.48 0.082 
UCEC 0.39 0.076 
UCS 0.062 
UVM 0.067 
